147 related articles for article (PubMed ID: 32667822)
1. Assessing Genitourinary Cancer Clinical Trial Accrual Sufficiency Using Archived Trial Data.
Stensland K; Kaffenberger S; Canes D; Galsky M; Skolarus T; Moinzadeh A
JCO Clin Cancer Inform; 2020 Jul; 4():614-622. PubMed ID: 32667822
[TBL] [Abstract][Full Text] [Related]
2. Estimating the rate and reasons of clinical trial failure in urologic oncology.
Stensland KD; DePorto K; Ryan J; Kaffenberger S; Reinstatler LS; Galsky M; Canes D; Skolarus TA; Moinzadeh A
Urol Oncol; 2021 Mar; 39(3):154-160. PubMed ID: 33257221
[TBL] [Abstract][Full Text] [Related]
3. Assessing clinical trial failure risk factors and reasons in gastric cancer.
Zhang Z; Yin J; Yue Y; Su Y; Jiang H
BMC Gastroenterol; 2022 Nov; 22(1):496. PubMed ID: 36451088
[TBL] [Abstract][Full Text] [Related]
4. Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials.
Paul K; Sathianathen N; Dahm P; Le C; Konety BR
J Urol; 2019 Aug; 202(2):385-391. PubMed ID: 31074679
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the Frequency, Characteristics, and Reasons for Termination of Spine-related Clinical Trials.
Caruana DL; Nam-Woo Kim D; Galivanche AR; David WB; Justen MA; Moushey AM; Sheth AH; Paranjpe MD; Grauer JN
Clin Spine Surg; 2022 Aug; 35(7):E596-E600. PubMed ID: 35351841
[TBL] [Abstract][Full Text] [Related]
6. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.
Schroen AT; Petroni GR; Wang H; Gray R; Wang XF; Cronin W; Sargent DJ; Benedetti J; Wickerham DL; Djulbegovic B; Slingluff CL
Clin Trials; 2010 Aug; 7(4):312-21. PubMed ID: 20595245
[TBL] [Abstract][Full Text] [Related]
7. Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis.
Mitchell AP; Hirsch BR; Abernethy AP
Trials; 2014 Mar; 15():92. PubMed ID: 24661848
[TBL] [Abstract][Full Text] [Related]
8. Center-Specific Modeling Predicts Cancer Trial Accrual More Accurately Than Investigators and Random Effects Modeling at 16 Cancer Centers.
Tate WR; Abraham I; Cranmer LD
JCO Clin Cancer Inform; 2019 Jun; 3():1-12. PubMed ID: 31173517
[TBL] [Abstract][Full Text] [Related]
9. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.
Schroen AT; Petroni GR; Wang H; Thielen MJ; Sargent D; Benedetti JK; Cronin WM; Wickerham DL; Wang XF; Gray R; Cohn WF; Slingluff CL; Djulbegovic B
Clin Trials; 2011 Oct; 8(5):591-600. PubMed ID: 21878447
[TBL] [Abstract][Full Text] [Related]
10. Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination.
Williams RJ; Tse T; DiPiazza K; Zarin DA
PLoS One; 2015; 10(5):e0127242. PubMed ID: 26011295
[TBL] [Abstract][Full Text] [Related]
11. Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors.
Khunger M; Rakshit S; Hernandez AV; Pasupuleti V; Glass K; Galsky MD; Grivas P
Oncologist; 2018 Dec; 23(12):1494-1499. PubMed ID: 30068783
[TBL] [Abstract][Full Text] [Related]
12. Early Termination of Oncology Clinical Trials in the United States.
Zhang E; DuBois SG
Cancer Med; 2023 Mar; 12(5):5517-5525. PubMed ID: 36305832
[TBL] [Abstract][Full Text] [Related]
13. Early termination of cardiovascular trials as a consequence of poor accrual: analysis of ClinicalTrials.gov 2006-2015.
Baldi I; Lanera C; Berchialla P; Gregori D
BMJ Open; 2017 Jun; 7(6):e013482. PubMed ID: 28619765
[TBL] [Abstract][Full Text] [Related]
14. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.
Schroen AT; Petroni GR; Wang H; Thielen MJ; Gray R; Benedetti J; Wang XF; Sargent DJ; Wickerham DL; Cronin W; Djulbegovic B; Slingluff CL
Clin Cancer Res; 2012 Jan; 18(1):256-62. PubMed ID: 21976533
[TBL] [Abstract][Full Text] [Related]
15. Design-phase prediction of potential cancer clinical trial accrual success using a research data mart.
London JW; Balestrucci L; Chatterjee D; Zhan T
J Am Med Inform Assoc; 2013 Dec; 20(e2):e260-6. PubMed ID: 23851466
[TBL] [Abstract][Full Text] [Related]
16. Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials.
Cheng SK; Dietrich MS; Dilts DM
Clin Cancer Res; 2011 Apr; 17(7):1947-55. PubMed ID: 21447723
[TBL] [Abstract][Full Text] [Related]
17. Understanding the Termination of Urologic Cancer Clinical Trials: Insights and Challenges.
Alhajahjeh A; Hmeidan M; Elatrsh M; Al-Abbadi F; Kakish D; Sukerji R; Salah M; Al Awamlh BAH; Lee DI; Shahait M
JCO Glob Oncol; 2024 Jan; 10():e2300349. PubMed ID: 38207249
[TBL] [Abstract][Full Text] [Related]
18. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement.
Tang C; Sherman SI; Price M; Weng J; Davis SE; Hong DS; Yao JC; Buzdar A; Wilding G; Lee JJ
Clin Cancer Res; 2017 Mar; 23(6):1414-1421. PubMed ID: 28275168
[No Abstract] [Full Text] [Related]
19. Analysis of factors leading to early termination in glioblastoma-related clinical trials.
Shah HA; Mishra A; Gouzoulis MJ; Ben-Shalom N; D'Amico RS
J Neurooncol; 2022 Jul; 158(3):489-495. PubMed ID: 35648307
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000-2019.
Gresham G; Meinert JL; Gresham AG; Meinert CL
JAMA Netw Open; 2020 Aug; 3(8):e2014682. PubMed ID: 32845329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
